Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type.

Area of Science:

• Oncology
• Hematology
• Dermatology

Background:

• Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a rare, aggressive non-Hodgkin lymphoma.
• Elderly patients are predominantly affected, often with a poor prognosis.
• Rituximab, an anti-CD20 monoclonal antibody, is effective in nodal lymphomas but its role in PCDLBCL-LT requires further evaluation.

Purpose of the Study:

• To evaluate the risk-benefit ratio of single-agent rituximab for PCDLBCL-LT.
• To assess objective response rates, adverse effects, disease-free survival, and overall survival.

Main Methods:

• Retrospective study of 8 patients with PCDLBCL-LT treated with single-agent rituximab.
• Evaluation of clinical endpoints including objective response rate, adverse events, and survival data.

Main Results:

• Objective response rate of 75% after 4 courses of rituximab.
• 100% of patients experienced relapse, with a median disease-free survival of 5.25 months.
• Excellent tolerance observed, with only one Grade I adverse event.

Conclusions:

• Single-agent rituximab demonstrates a high initial objective response rate in PCDLBCL-LT but lacks durable therapeutic effects, with all patients relapsing.
• While less effective than combination therapy, rituximab monotherapy offers superior tolerance and may be suitable for short-term palliative care in select patients.
• The risk-benefit profile suggests rituximab monotherapy is a well-tolerated option for palliative treatment, though not curative.